Company intelligence / Profile preview

IMV

Dartmouth, Nova Scotia, Canadaimv-technologies.us ↗

Ownership: Private
Development stage: Other

Overview

IMV Inc. was a Canadian clinical-stage biotech company focused on developing cancer immunotherapies and infectious disease vaccines using its DPX™ platform, which delivers peptides, proteins, and mRNA. Its lead oncology candidate, maveropepimut-S, was in Phase 2b for DLBCL and ovarian cancer. The company faced financial difficulties, filed for bankruptcy in 2023, and its assets were subsequently acquired by BioVaxys Technology Corp. in February 2024.

Therapeutic areas: Infectious DiseasesOncology
Modalities: VaccinePeptidesLipid nanoparticle delivery therapy
Industry: Biotech

Partnerships

Merck/MSD (Combination trials with pembrolizumab)Zoetis (Animal health licensee for technology use in veterinary vaccines)SpayVac for Wildlife Inc. (Licensee)Merck KGaA (License agreement related to survivin proteins)

Beyond the preview

Go deeper on IMV.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IMV.

Explore the full profile